Clinical trials: multiple sclerosis
Urinary Incontinence, Multiple Sclerosis
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.
- Conditions
- Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder
- Trial name
- NCT01600716
- Testing
- OnabotulinumtoxinA
- Where
- 10 sites in United States, Belgium and 6 more
- Volunteers
- 144 people
- Sponsor
- Allergan
Multiple Sclerosis, Optic Neuritis
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
The current study is a continuation of the 5 year extension study of the phase III CHAMPS study (see reference). This study was designed to determine if immediate initiation of therapy with Interferon Beta-1a (AVONEX) after a…
- Conditions
- Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome
- Trial name
- CHAMPIONS10 (NCT00179478)
- Testing
- interferon beta 1a 30 ug IM once weekly
- Where
- 26 sites in United States, Canada
- Volunteers
- 155 people
- Sponsor
- Beth Israel Deaconess Medical Center
Multiple Sclerosis, Relapsing-Remitting
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
The purpose of this study is to determine if a higher dose of study drug is more effective in preventing relapses in patients with Multiple Sclerosis.
- Trial name
- NCT00235989
- Testing
- Interferon beta 1b (Betaseron, BAY86-5046)
- Where
- 17 sites in United States
- Volunteers
- 63 people
- Sponsor
- Bayer
Multiple Sclerosis
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants who Have Participated in Cladribine Clinical Trials
- Trial name
- PREMIERE (NCT01013350)
- Where
- United States
- Volunteers
- 1,161 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
The study AC-058B301 (OPTIMUM; NCT02425644) has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with relapsing multiple sclerosis (RMS).
- Trial name
- OPTIMUM-LT (NCT03232073)
- Testing
- Ponesimod
- Where
- 148 sites in United States, Belarus and 26 more
- Volunteers
- 877 people
- Sponsor
- Actelion
Multiple Sclerosis, Infusion Reaction
Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab
This 6-month randomized controlled pilot study will determine whether there is some evidence that cetirizine is better tolerated than diphenhydramine without an increase in Infusion-Related Reactions (IRRs) in subjects receiving…
- Trial name
- PRECEPT (NCT04175834)
- Testing
- cetrizine, diphenhydramine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Providence Health & Services
Multiple Sclerosis, Cognitive Ability, General
Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis
The purpose of this study is to see if treatment with Ginkgo improves cognitive function in people with multiple sclerosis who have cognitive problems.
- Trial name
- NCT00841321
- Testing
- Ginkgo biloba
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- US Department of Veterans Affairs
Relapsing-remitting Multiple Sclerosis (RRMS)
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
RED4MS is a clinical trial to assess the safety and tolerability of autologous peptide coupled red blood cells (CLS12311) in patients with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- RED4MS (NCT06430671)
- Testing
- CLS12311 low, CLS12311 medium, CLS12311 high
- Where
- 8 sites in Czechia, Germany and 2 more
- Volunteers
- 11 people
- Sponsor
- Cellerys AG
Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in RMS or PPMS.
- Trial name
- NCT02688985
- Testing
- Ocrelizumab, Lumbar Puncture, Methyloprednisolone
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 131 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis
A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS)
This is a randomized, double-blind pilot clinical trial to test a novel treatment approach to rehabilitate fine motor function in individuals living with progressive multiple sclerosis (MS) using anodal transcranial direct…
- Trial name
- NCT03499314
- Testing
- Active RS-tDCS +At-Home Manual Dexterity Training, Manual dexterity training
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- NYU Langone Health
Relapsing Multiple Sclerosis
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis.
- Trial name
- NCT01412333
- Testing
- Interferon beta-1a, Ocrelizumab
- Where
- 165 sites in United States, Argentina and 22 more
- Volunteers
- 835 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Depression
Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis
This study will determine whether fish oil can reduce depression in people with multiple sclerosis (MS) who are mild to moderately depressed and are currently taking antidepressant medication.
- Trial name
- NCT00122954
- Testing
- Fish oil concentrate
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Oregon Health and Science University
Multiple Sclerosis
Cerebellar tDCS and Balance Training in PwMS
Many people with multiple sclerosis (PwMS) have decreased balance and postural control, gait deficits, and a high frequency of falls.
- Trial name
- NCT04391023
- Testing
- Balance Training, 2 mA Transcranial Direct Current Stimulation, 4 mA Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Iowa
Spasticity
Study of SPARC1103 in Subjects With Spasticity
Study of SPARC1103 in subjects with spasticity
- Trial name
- NCT02027025
- Testing
- SPARC1103 low dose, SPARC1103 high dose
- Where
- 23 sites in United States, Russia and 1 more
- Volunteers
- 142 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Multiple Sclerosis
Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series
This study evaluates the effectiveness of personalized physical activity coaching combined with the use of a physical activity monitor to support increased levels of daily physical activity in individuals with multiple sclerosis.
- Trial name
- NCT02335450
- Testing
- Motivational Interviewing, Wristband physical activity monitor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oakland University
Relapsing-Remitting Multiple Sclerosis
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
The main purpose of this study was to investigate the effectiveness of cladribine tablets in a UK real-world setting.
- Trial name
- NCT04997148
- Where
- 8 sites in United Kingdom
- Volunteers
- 116 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis
The purpose of this study is to learn about how the antioxidant, lipoic acid, works in the body and how it may help in the management of relapsing remitting and secondary progressive multiple sclerosis.
- Trial name
- NCT00997438
- Testing
- Lipoic Acid
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Portland VA Medical Center
Multiple Sclerosis
Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis
Randomized Double-Blind Efficacy and safety study of Autologous HB-adMSCs versus placebo for the treatment of Multiple Sclerosis. This study will be for 24 subjects with 6 infusions over a 52 week period.
- Trial name
- HBMS01 (NCT05116540)
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hope Biosciences Research Foundation
Relapsing-Remitting Multiple Sclerosis
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and…
- Trial name
- ENDORSE (NCT00835770)
- Testing
- dimethyl fumarate
- Where
- 246 sites in United States, Australia and 32 more
- Volunteers
- 1,736 people
- Sponsor
- Biogen
Multiple Sclerosis
Low Load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis
The Primary Aim of this research study is to determine the feasibility of 8 weeks of physical therapy strengthening exercises using blood flow restriction (BFR) in people with multiple sclerosis (MS) who have moderate-to-severe…
- Trial name
- BFR-MS (NCT04633759)
- Testing
- Blood Flow Restriction Exercise
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Colorado, Denver